CDK4 and dedifferentiated liposarcoma: In the Phase Ib trial in patients with advanced WDLPS or DDLPS, combining an MDM2 inhibitor with a CDK4/6 inhibitor ribociclib was demonstrated to have an initial anti-tumor effect and a controlled safety profile (74).